Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 376

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 376
---
 from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements; and

•

an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on financial statements.

We would cease to qualify as an emerging growth company on the date that is the earliest of: (i) December 31, 2026, (ii) the last day of the fiscal year in which we have more than $1.235 billion in total annual gross revenues, (iii) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC, which means the market value of our common shares that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, or (iv) the date on which we have issued more than $1.0 billion of non-convertible debt over the prior three-year period. We may choose to take advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this proxy statement/prospectus. Accordingly, the information contained herein may be different than you might obtain from other public companies in which you hold equity interests.

<div align='center'>205</div>

TABLE OF CONTENTS

### EXECUTIVE COMPENSATION

#### Executive Officer and Director Compensation
None of our executive officers or directors have received any cash compensation for services rendered to us and no executive officer or director of Iris has received cash compensation for services rendered to ParentCo prior to the Business Combination. In connection with the Business Combination and following the transactions in connection therewith, ParentCo’s directors, executive officers and other employees will begin receiving compensation from ParentCo.

Subsequent to the closing of the IPO, Iris began paying a then-affiliate of the Sponsor, Tribe Capital, a total of $10,000 per month for office space, secretarial and administrative services provided to members of Iris’s management team. On March 11, 2024, the Company entered into the Agreement with Arrow. Pursuant to the Agreement, Arrow will provide the Services to the Company. In exchange for the Services, the Company will pay to Arrow $10,000 per month, beginning January 1, 2024, and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation. On August 30, 2024, the Company amended the Agreement with Arrow. In exchange